Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXAS1 | P24557 | 13/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | LTA4H | P09960 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | NOS1 | P29475 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8995364 | 0.93 | QPCT (0.69) | TBXAS1KDM4EKMT2AMEN1LMNA | |
| SCHEMBL25344191 | 0.85 | TBXAS1 (0.64) | TBXAS1KDM4EALDH1A1LTA4HKMT2A | |
| SCHEMBL29569737 | 0.85 | TBXAS1 (0.64) | TBXAS1KDM4EALDH1A1LTA4HKMT2A | |
| SCHEMBL8995204 | 0.84 | TBXAS1 (0.51) | TBXAS1KDM4EALDH1A1MAPK1LTA4H | |
| SCHEMBL10856315 | 0.83 | TBXAS1 (1.00) | TBXAS1KMT2AMEN1LMNA | |
| SCHEMBL10856322 | 0.83 | TBXAS1 (1.00) | TBXAS1KMT2AMEN1LMNA | |
| SCHEMBL8995313 | 0.82 | TBXAS1 (0.74) | TBXAS1KDM4EALDH1A1MAPK1LTA4H | |
| SCHEMBL8690248 | 0.81 | KMT2A (0.83) | TBXAS1KDM4EALDH1A1MAPK1LTA4H | |
| SCHEMBL8684965 | 0.81 | MAPK1 (1.00) | TBXAS1KDM4EALDH1A1MAPK1LTA4H | |
| SCHEMBL76839 | 0.81 | KDM4E (0.72) | TBXAS1KDM4EALDH1A1MAPK1LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116940562-A | Acetamido-phenylbenzamide derivatives and methods of use thereof | 希华医药有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4225745-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Athenex, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022076662-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ATHENEX, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | Health Hope Pharma Limited (HK) | 2022-04-07 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| EP-1940823-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
| EP-0557787-B1 | Imidazolylphenol derivatives, medicaments containing them and a process for the preparation of these compounds and medicaments | GRUENENTHAL GMBH (DE) | 2000-05-24 | — | — | EP | disclosed |
| US-5496844-A | Indole derivatives | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0639567-A1 | INDOLE DERIVATIVE | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1995-02-22 | — | — | EP | disclosed |
| US-5356921-A | Exhibit 5-lipoxygenase and thromboxane synthase inhibiting activities; administering for disorders attributable to the action of leukotrienes and thromboxane A2 | GRUENENTHAL GMBH (DE) | 1994-10-18 | — | — | US | disclosed |
| EP-0557787-A1 | Imidazolylphenol derivatives, medicaments containing them and a process for the preparation of these compounds and medicaments | Grünenthal GmbH (DE) | 1993-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220106301-A1 | ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME | ABCB1, ABCC1, UGT2B7 | TBXAS1 1100/4885KDM4E 2232/4885ALDH1A1 102/4885 |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | TBXAS1 2072/4885KDM4E 1737/4885ALDH1A1 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.